Company culture matters (1): Best practice in Post Merger Integration:
BLOG


- Jul 15, 2020
HTA considerations II: regulators, HTA bodies and payers: the earlier - the better

- Jul 15, 2020
HTA considerations I: pharma industry: the earlier - the better

- Jul 1, 2020
Randomized controlled trials are the shell of the evidence construction...

- Jul 1, 2020
How Real-World Evidence augments randomized controlled trials...

- Jun 4, 2020
Effective distributor management requires clear definitions of R&Rs

- May 14, 2020
Virtual offices also have a floor-plan!

- May 14, 2020
5 tips for running a successful virtual organisation

- May 6, 2020
VSCR New advanced Online-Module: From Clinical Evidence to HTA 15th - 16th June 2020

- Apr 1, 2020
5 simple tips for successful webinars & online meetings

- Mar 30, 2020
Flattening the COVID-19 (Coronavirus) curve works by one simple measure: SOLIDARITY

- Mar 30, 2020
Health statistics put into perspective - Coronavirus statistics (example: Germany)

- Mar 4, 2020
Worried about coronavirus infection? Consider playing the lottery!

- Mar 1, 2020
Over a month on from Brexit - lose / lose looks like this in the top 5 economies & pharma markets

- Feb 21, 2020
VSCR new advanced HTA course from 20th - 22nd April 2020 in Vienna

- Feb 6, 2020
2020: digital health & new therapeutic approaches require...

- Jan 30, 2020
Executive challenges 2020

- Jan 30, 2020
Pharma objectives 2020

- Jan 9, 2020
Entering a new decade of global burden of disease rankings? (2)

- Jan 9, 2020
Entering a new decade of global burden of disease rankings? (1)